Close Menu

NEW YORK – Biodesix today priced its initial public offering of 4 million shares of its common stock at $18 per share for anticipated gross proceeds of $72 million.

Shares of the Boulder, Colorado-based firm will begin trading on the Nasdaq today under ticker symbol "BDSX".

Biodesix is also granting the IPO underwriters a 30-day option to purchase an additional 600,000 shares at the offering price, which would raise an additional $10.8 million. The firm expects the offering to close on Oct. 30.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.